PDMR Shareholding/Share Incentive Plan and TVRs
Diaceutics PLC has announced that on February 27, 2026, trustees purchased ordinary shares on behalf of three Persons Discharging Managerial Responsibilities (PDMRs) as part of the company's Share Incentive Plan, with an equivalent number of shares granted as a matched award. Susanne Munksted purchased 99 shares at 149.9 pence each, Jordan Clark purchased 100 shares at 149.9 pence each, and Nick Roberts purchased 100 shares at 149.9 pence each, with all transactions occurring on March 2, 2026. The total number of issued shares remains unchanged at 84,917,283.
Select text to share a quote on X · sign in to keep highlights & notes in your DXRX notes
New York, Belfast and London, 3 March 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 27 February 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by utilising a balance of previously allotted but unallocated Shares held by the UK Trust on 2 March 2026. The Trust will continue to hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.
As a result, the number of Share Diaceutics has in issue remains unchanged at 84,917,283 Shares. This figure may continue to be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Susanne Munksted |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Precision Medicine Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 149.9 p | 99 | |
| Conditional share award: | ||
| Price(s) | Volume(s) | |
| Nil | 99 | |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Jordan Clark |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Data Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 149.9 p | 100 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 100 | |
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a. | Name | Nick Roberts |
| 2 | Reason for notification | |
| a. | Position/Status | Chief Finance Officer |
| b. | Initial notification/ Amendment | Initial |
| a. | Name | Diaceutics PLC |
| b. | LEI | 213800VEWQBB39ZB8J81 |
| a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of £ 0.002 each ISIN: GB00BJQTGV64 |
| c. | Price(s) and volume(s) | Share purchase: |
| Price(s) | Volume(s) | |
| 149.9 p | 100 | |
| Matched share award: | ||
| Price(s) | Volume(s) | |
| Nil | 100 | |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.